Sub Heading

Clinical Trials Details

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

IRB Protocol Number
Mirati Krystal MRTX849

Clinical Trial Categories

  • Solid Tumors
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: Men or women, ages 18 and older, diagnosed with advanced cancer, which has a KRAS G12C mutation. 

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.